Terms: = Liver cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Treatment
150 results:
1. Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment.
Elmetwalli A; Abdel-Monem MO; El-Far AH; Ghaith GS; Albalawi NAN; Hassan J; Ismail NF; El-Sewedy T; Alnamshan MM; ALaqeel NK; Al-Dhuayan IS; Hassan MG
Med Oncol; 2024 Apr; 41(5):106. PubMed ID: 38575697
[TBL] [Abstract] [Full Text] [Related]
2. Survey of lived experiences and challenges in hepatitis B management and treatment.
Freeland C; Adjei C; Wallace J; Wang S; Hicks J; Adda D; James C; Cohen C
BMC Public Health; 2024 Apr; 24(1):944. PubMed ID: 38566070
[TBL] [Abstract] [Full Text] [Related]
3. Aldehyde Dehydrogenase 2 (aldh2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay.
Ferreira IC; Torrejón E; Abecasis B; Alexandre BM; Gomes RA; Verslype C; van Pelt J; Barbas A; Simão D; Bandeiras TM; Bortoluzzi A; Rebelo SP
SLAS Discov; 2024 Apr; 29(3):100154. PubMed ID: 38521503
[TBL] [Abstract] [Full Text] [Related]
4. Research Progress on the Correlation between Acetaldehyde Dehydrogenase 2 and Hepatocellular Carcinoma Development.
Yang D; Hu Y; Yang J; Tao L; Su Y; Wu Y; Yao Y; Wang S; Ye S; Xu T
J Pharmacol Exp Ther; 2024 Apr; 389(2):163-173. PubMed ID: 38453527
[TBL] [Abstract] [Full Text] [Related]
5. Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study.
Simmons DJ; Valerio SJ; Thomas DS; Healey MJ; Jiang Z; Levingston Mac Leod JM; Lin Y; Sah J
Adv Ther; 2024 Apr; 41(4):1711-1727. PubMed ID: 38443649
[TBL] [Abstract] [Full Text] [Related]
6. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological, metastatic and prognostic features of stage IV esophageal adenocarcinoma versus squamous cell carcinoma: a SEER database analysis.
Pan L; Zhang Y; Gao Y; Qiu J
Chin Clin Oncol; 2024 Feb; 13(1):2. PubMed ID: 38372056
[TBL] [Abstract] [Full Text] [Related]
8. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
[TBL] [Abstract] [Full Text] [Related]
9. Discovery of potent thiazolidin-4-one sulfone derivatives for inhibition of proliferation of osteosarcoma in vitro and in vivo.
Chen X; Luo Z; Hu Z; Sun D; He Y; Lu J; Chen L; Liu S
Eur J Med Chem; 2024 Feb; 266():116082. PubMed ID: 38232462
[TBL] [Abstract] [Full Text] [Related]
10. Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
Kobayashi S; Nakachi K; Ikeda M; Konishi M; Ogawa G; Sugiura T; Yanagimoto H; Morinaga S; Wada H; Shimada K; Takahashi Y; Nakagohri T; Kamata K; Shimizu Y; Ajiki T; Hirano S; Gotohda N; Ueno M; Okusaka T; Furuse J
Eur J Surg Oncol; 2024 Feb; 50(2):107324. PubMed ID: 38157649
[TBL] [Abstract] [Full Text] [Related]
11. Construction and validation of the predictive model for gallbladder cancer liver metastasis patients: a SEER-based study.
Zhang W; Chen Z; Sa B
Eur J Gastroenterol Hepatol; 2024 Jan; 36(1):129-134. PubMed ID: 37994618
[TBL] [Abstract] [Full Text] [Related]
12. aldh2 dysfunction and alcohol cooperate in cancer stem cell enrichment.
Flashner S; Shimonosono M; Tomita Y; Matsuura N; Ohashi S; Muto M; Klein-Szanto AJ; Alan Diehl J; Chen CH; Mochly-Rosen D; Weinberg KI; Nakagawa H
Carcinogenesis; 2024 Feb; 45(1-2):95-106. PubMed ID: 37978873
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study.
Yao Y; Wang Y; Du Y; Jiang F; Liang H; Bi M; Xie H; Peng W; Pan Y
Int Immunopharmacol; 2023 Dec; 125(Pt B):111147. PubMed ID: 37956490
[TBL] [Abstract] [Full Text] [Related]
14. Is surgical treatment of hepatocellular carcinoma at high-volume centers worth the additional cost?
Shaikh CF; Woldesenbet S; Munir MM; Lima HA; Moazzam Z; Endo Y; Alaimo L; Azap L; Yang J; Katayama E; Dawood Z; Pawlik TM
Surgery; 2024 Mar; 175(3):629-636. PubMed ID: 37741780
[TBL] [Abstract] [Full Text] [Related]
15. Research progress on tamoxifen and its analogs associated with nuclear receptors.
Dong N; Du Y; Zheng Y; Zhang H; Lv H; Yan Z
Future Med Chem; 2023 Aug; 15(15):1427-1442. PubMed ID: 37706220
[TBL] [Abstract] [Full Text] [Related]
16. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Salani F; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Schirripa M; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Scartozzi M; Cascinu S; Casadei-Gardini A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7565-7577. PubMed ID: 36976353
[TBL] [Abstract] [Full Text] [Related]
17. Predicting Limited Survival After Resection of Synchronous Colorectal liver Metastases: a Propensity Score Matched Comparison Between The Primary First And The Simultaneous Strategy.
Addeo P; Foguenne M; Guerra M; Cusumano C; Paul C; Faitot F; Fiore L; De Mathelin P; Bachellier P
J Gastrointest Surg; 2023 Jun; 27(6):1141-1151. PubMed ID: 36857012
[TBL] [Abstract] [Full Text] [Related]
18. Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy.
Köksal M; Kersting L; Schoroth F; Garbe S; Koch D; Scafa D; Sarria GR; Leitzen C; Heine A; Holderried T; Brossart P; Zoga E; Attenberger U; Schmeel LC
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5965-5973. PubMed ID: 36607428
[TBL] [Abstract] [Full Text] [Related]
19. Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy.
Thormann M; Heitmann F; Wrobel V; Barajas Ordonez F; Pech M; Surov A; Damm R; Omari J
Rofo; 2023 Mar; 195(3):217-223. PubMed ID: 36283404
[TBL] [Abstract] [Full Text] [Related]
20. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some cancers in Patients With Diabetes.
Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
[TBL] [Abstract] [Full Text] [Related]
[Next]
